Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.50K | $16.3K | $17.8K | — | — | — | — | — | — |
| Revenue growth | — | 262.4% | 9.0% | — | — | — | — | — | — |
| Gross profit | $1.25K | $4.67K | $4.36K | — | — | — | — | — | — |
| Gross margin | 27.9% | 28.6% | 24.5% | — | — | — | — | — | — |
| Operating income | -$31.3K | -$66.7K | -$46.5K | — | — | — | — | — | — |
| Operating margin | -694.7% | -409.2% | -261.8% | — | — | — | — | — | — |
| Net income | -$31.3K | -$67.7K | -$46.5K | -$158M | -$502K | -$486K | -$472K | -$490K | -$1.29M |
| Net margin | -694.7% | -415.3% | -261.8% | — | — | — | — | — | — |
| EPS (diluted) | $0.00 | $0.00 | $0.00 | -$9.72 | -$0.02 | -$0.02 | -$0.02 | -$0.02 | -$0.04 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$25.9K | -$62.5K | -$24.4K | -$80.2K | -$77.8K | -$68.4K | -$46.7K | -$61.3K | -$65.2K |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $14.3K | $29.4K | $52.9K | $39.9K | $11.1K | $734.00 | $638.00 | $862.00 | $786.00 |
| Total assets | $20.9K | $35.1K | $58.9K | $39.9K | $11.1K | $734.00 | $638.00 | $862.00 | $786.00 |
| Total liabilities | $12.7K | $5.32K | $11.6K | $400K | $873K | $1.35M | $1.82M | $2.30M | $619K |
| Shareholders' equity | $8.20K | $29.8K | $47.3K | -$360K | -$862K | -$1.35M | -$1.82M | -$2.30M | -$619K |
| Retained earnings | -$647K | -$715K | -$762K | -$159M | -$160M | -$160M | -$161M | -$161M | -$162M |
| Shares (wtd avg diluted) | 76.3M | 15.3M | 15.3M | 29.3M | 29.3M | 29.3M | 29.3M | 29.3M | 33.2M |
Every figure is extracted from BIOFORCE NANOSCIENCES HOLDINGS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.